Please assess the completion status of the following clinical trial:

Trial Title: Antenatal Azithromycin to Prevent Preterm Birth in Pregnant Women With Vaginal Cerclage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Gestational age (14-34 weeks).~2. Pregnant women who underwent vaginal cerclage (either history- based or ultrasound based vaginal cerclage)~History based cerclage:~* History of one or more second-trimester pregnancy losses related to painless cervical dilatation and in absence of labor or abruptio placentae; OR~* Prior cerclage due to painless cervical dilation in the second trimester~Ultrasound based cerclage:~Current singleton pregnancy, prior spontaneous preterm birth at less than 34 weeks of gestation, and short cervical length (less than 25 mm) before 24 weeks of gestation~Exclusion Criteria:~1. Multiple pregnancy.~2. Current or past history of medical diseases (Diabetes Milletus, Hypertension, Systemic Lupus Erythematosus, Cardiac diseases, etc ).~3. Adverse perinatal outcome due to abdominal trauma.~4. Structural fetal anomalies detected during anomaly scan.~5. Allergy to Azithromycin

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Azithromycin group (Type: ACTIVE_COMPARATOR): women will receive 500mg Azithromycin (Zithrokan®, Hikma, Egypt) one tablet orally twice daily for three days in 3 courses at 14 weeks, 24 weeks and 32 weeks in addition to routine usual antenatal care.
- Control group (Type: NO_INTERVENTION): women will receive routine antenatal care without antibiotic prophylaxis after cerclage.

Based on this trial design, predict the completion outcome and termination type (if applicable).